Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

被引：0
|
作者：
Cheryl S. W. Li
Kevin Sweeney
Carol Cronenberger
机构：
[1] Pfizer Global Product Development,Clinical Pharmacology/Pharmacometrics
[2] Pfizer Inc.,Clinical Pharmacology/Pharmacometrics
[3] Pfizer Global Product Development,Clinical Pharmacology/Pharmacometrics
[4] Pfizer Inc.,undefined
[5] Pfizer Global Product Development,undefined
[6] Pfizer Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
Bevacizumab; Biosimilar; Non-small cell lung cancer; PF-06439535; Population pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：487 / 499
页数：12
相关论文
共 50 条
  • [1] Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer
    Li, Cheryl S. W.
    Sweeney, Kevin
    Cronenberger, Carol
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 487 - 499
  • [2] A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.
    Socinski, Mark A.
    Von Pawel, Joachim
    Kasahara, Kazuo
    Bondarenko, Igor
    Syrigos, Konstantinos
    Vladimirov, Vladimir Ivanovich
    Bryl, Maciej
    Zereu, Manuela
    Bair, A. H.
    Hilton, Fiona
    Liau, Katherine Faye
    Herbst, Roy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] PF-06439535 (a bevacizumab biosimilar) for non-small cell lung cancer: subgroup analysis
    Okano, Yoshio
    Ishikawa, Tomofumi
    Hiro, Shintaro
    Hirano, Yoko
    Tajima, Kentaro
    Kasahara, Kazuo
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
    Niels Reinmuth
    Maciej Bryl
    Igor Bondarenko
    Kostas Syrigos
    Vladimir Vladimirov
    Manuela Zereu
    Angel H. Bair
    Fiona Hilton
    Katherine Liau
    Kazuo Kasahara
    BioDrugs, 2019, 33 : 555 - 570
  • [5] PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
    Reinmuth, Niels
    Bryl, Maciej
    Bondarenko, Igor
    Syrigos, Kostas
    Vladimirov, Vladimir
    Zereu, Manuela
    Bair, Angel H.
    Hilton, Fiona
    Liau, Katherine
    Kasahara, Kazuo
    BIODRUGS, 2019, 33 (05) : 555 - 570
  • [6] Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer
    Owen, Joel S.
    Rackley, Russell J.
    Hummel, Matthew A.
    Roepcke, Stefan
    Huang, Hannah
    Liu, Mark
    Idris, Tazeen A.
    Murugesan, Sundara Moorthi Nainar
    Marwah, Ashwani
    Loganathan, Subramanian
    Ranganna, Gopinath
    Barve, Abhijit
    Waller, Cornelius F.
    Socinski, Mark A.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48 (06) : 675 - 689
  • [7] Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer
    Joel S. Owen
    Russell J. Rackley
    Matthew A. Hummel
    Stefan Roepcke
    Hannah Huang
    Mark Liu
    Tazeen A. Idris
    Sundara Moorthi Nainar Murugesan
    Ashwani Marwah
    Subramanian Loganathan
    Gopinath Ranganna
    Abhijit Barve
    Cornelius F. Waller
    Mark A. Socinski
    European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48 : 675 - 689
  • [8] Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
    Zhou, Z.
    Lu, S.
    Qin, S.
    Chen, J.
    Gu, K.
    Sun, P.
    Pan, Y.
    Yu, G.
    Ma, K.
    Shi, J.
    Sun, Y.
    Yang, L.
    Chen, P.
    Liu, A.
    He, J.
    Li, X.
    Wang, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1393 - S1394
  • [9] Safety of Bevacizumab (Bv) in Superannuated Patients with Non-squamous Non-small Cell Lung Cancer
    Charpidou, Andriani
    Vassos, Dimitrios
    Tsimpoukis, Sotirios
    Demertzis, Panagiotis
    Gkiozos, Ioannis
    Syrigos, Kostas
    CHEST, 2014, 145 (03)
  • [10] THE ADMINISTRATION OF BEVACIZUMAB FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES
    Fukunaga, Kentaro
    Kawashima, Satoru
    Yoshihashi, Saiko
    Seto, Ruriko
    Kanda, Rie
    Higami, Yuichi
    Goto, Kenichi
    Ryujin, Yasushi
    Nakagawa, Hiroaki
    Van Tho, Nguyen
    Yamaguchi, Masafumi
    Oguma, Tetuya
    Nagao, Taishi
    Ogawa, Emiko
    Nakano, Yasutaka
    RESPIROLOGY, 2013, 18 : 87 - 87
12345